Open AccessAbelacimab for Prevention of Venous Thromboembolism
Author(s) -
Peter Verhamme,
B. Alexander Yi,
Annelise Segers,
Janeen Salter,
Daniel M. Bloomfield,
Harry R. Büller,
Gary E. Raskob,
Jeffrey I. Weitz
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2105872
Subject(s) - medicine , venous thromboembolism , regimen , venous thrombosis , surgery , venography , group b , anesthesia , thrombosis
The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom